Galidesivir - BioCryst Pharmaceuticals

Drug Profile

Galidesivir - BioCryst Pharmaceuticals

Alternative Names: BCX-4430

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Developer BioCryst Pharmaceuticals; National Institute of Allergy and Infectious Diseases; Utah State University
  • Class Antivirals; Purine nucleosides; Pyrimidine nucleosides; Pyrroles; Pyrrolidines; Small molecules
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ebola virus infections; Marburg virus disease
  • Preclinical Middle East respiratory syndrome coronavirus; Yellow fever; Zika virus infection

Most Recent Events

  • 04 Oct 2017 Pharmacodynamics data from preclinical study in Ebola and Zika virus infections released by BioCryst Pharmaceuticals
  • 07 Aug 2017 BioCryst Pharmaceuticals plans a phase I trial for Ebola virus infections
  • 26 Oct 2016 Preclinical data from a in Zika virus infection presented at the IDWeek 2016 (IDW - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top